Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic.

Proceedings of the National Academy of Sciences of the United States of America
Joseph T WuKwok Yung Yuen

Abstract

Treatment strategies for severe cases of pandemic influenza have focused on antiviral therapies. In contrast, passive immunotherapy with convalescent blood products has received limited attention. We consider the hypothesis that a passive-immunotherapy program that collects plasma from a small percentage of recovered adults can harvest sufficient convalescent plasma to treat a substantial percentage of severe cases during a pandemic. We use a mathematical model to estimate the demand and supply of passive immunotherapy during an influenza pandemic in Hong Kong. If >5% of 20- to 55-year-old individuals recovered from symptomatic infection donate their plasma (donor percentage > 5%), >67% of severe cases can be offered convalescent plasma transfusion (treatment coverage > 67%) in a moderately severe epidemic (R (0) < 1.4 with 0.5% of symptomatic cases becoming severe). A donor percentage of 5% is comparable to the average blood donation rate of 38.1 donations per 1,000 people in developed countries. Increasing the donor percentage above 15% does not significantly boost the convalescent plasma supply because supply is constrained by plasmapheresis capacity during most stages of the epidemic. The demand-supply balance depends on th...Continue Reading

Associated Clinical Trials

Jun 12, 2012·Dr Ivan FN Hung

References

Mar 18, 2000·The Journal of Infectious Diseases·L SimonsenN J Cox
Dec 17, 2004·Nature·Christina E MillsMarc Lipsitch
Jul 15, 2005·PLoS Medicine·Helen J WearingMatt J Keeling
Aug 5, 2005·Science·Ira M LonginiM Elizabeth Halloran
Mar 7, 2006·PLoS Medicine·Chit Ming WongJoseph S M Peiris
Apr 6, 2006·Proceedings of the National Academy of Sciences of the United States of America·Timothy C GermannCatherine A Macken
Apr 28, 2006·Nature·Neil M FergusonDonald S Burke
Aug 31, 2006·Annals of Internal Medicine·Thomas C LukeStephen L Hoffman
Oct 5, 2007·The New England Journal of Medicine·Boping ZhouYi Guan
Mar 28, 2008·PLoS Medicine·Joël MossongW John Edmunds
May 13, 2009·Science·Christophe FraserUNKNOWN WHO Rapid Pandemic Assessment Collaboration
Jun 26, 2009·PLoS Medicine·Nicholas J WhiteTimothy M Uyeki
Aug 15, 2009·American Journal of Epidemiology·Nicole E BastaIra M Longini
Aug 22, 2009·Science·Jan Medlock, Alison P Galvani
Jun 26, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ivan F N HungKwok-Yung Yuen

❮ Previous
Next ❯

Citations

Jul 12, 2013·Proceedings. Biological Sciences·Daihai HeDavid J D Earn
Apr 12, 2012·Clinical Microbiology Reviews·Vincent C C ChengKwok-Yung Yuen
Jul 6, 2011·Experimental Biology and Medicine·Joseph T Wu, Benjamin J Cowling
Jan 21, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ivan Fn HungKwok-Yung Yuen
Jan 15, 2014·The Journal of Infectious Diseases·Guy Freeman, Benjamin J Cowling
Feb 20, 2016·American Journal of Epidemiology·Justin Lessler, Derek A T Cummings
Jan 6, 2015·Nature·Declan Butler
Jan 1, 2014·Chinese Science Bulletin = Kexue Tongbao·Lin Wang, Xiang Li
Jul 31, 2020·Critical Care : the Official Journal of the Critical Care Forum·Zhiheng XuYimin Li
Jan 1, 2010·Frontiers of Medicine in China·Kelvin Kai-Wang ToKwok-Yung Yuen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.